vomiting; fever and chills; fever and chills; significant and debilitating vertigo; Fluzone 08Nov2022; Fluzone 08Nov2022; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 36-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 08Nov2022 at 10:30 as dose 4 (booster), single (Lot number: GJ6796) at the age of 36 years intramuscular, in right arm for covid-19 immunisation; influenza vaccine (FLUZONE [INFLUENZA VACCINE]), on 08Nov2022 as dose 1, single (Lot number: UT7751MA), in left deltoid for immunisation. The patient's relevant medical history included: "ADHD" (unspecified if ongoing), notes: ADHD, Depression, Allergic Rhinitis; "Depression" (unspecified if ongoing), notes: ADHD, Depression, Allergic Rhinitis; "Allergic Rhinitis" (unspecified if ongoing), notes: ADHD, Depression, Allergic Rhinitis; "Latex Allergy" (unspecified if ongoing); "Sulfa Allergy" (unspecified if ongoing). Concomitant medication(s) included: CONCERTA; LEXAPRO; WELLBUTRIN; ALLEGRA [FEXOFENADINE HYDROCHLORIDE]; FAMOTIDINE. Past drug history included: Wasps, reaction(s): "Drug allergy: Wasps". Vaccination history included: BNT162b2 (Dose Number: 3, Batch/Lot No: FC3184, Route of Administration: Intramuscular), administration date: 21Oct2021, when the patient was 35-year-old, for covid-19 immunization; BNT162b2 (Dose Number: 2, Batch/Lot No: EL3247, Location of injection: Arm Left, Route of Administration: Intramuscular), administration date: 25Jan2021, when the patient was 34-year-old, for covid-19 immunization; BNT162b2 (Dose Number: 1, Batch/Lot No: EK4176, Location of injection: Arm Left, Route of Administration: Intramuscular), administration date: 04Jan2021, when the patient was 34-year-old, for covid-19 immunization. The following information was reported: OFF LABEL USE (non-serious), PRODUCT USE ISSUE (non-serious) all with onset 08Nov2022, outcome "unknown" and all described as "Fluzone 08Nov2022"; PYREXIA (non-serious), CHILLS (non-serious) all with onset 09Nov2022, outcome "recovering" and all described as "fever and chills"; VERTIGO (non-serious) with onset 09Nov2022, outcome "recovering", described as "significant and debilitating vertigo"; VOMITING (non-serious) with onset 09Nov2022 at 17:00, outcome "recovering". The events "fever and chills", "significant and debilitating vertigo" and "vomiting" required physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of pyrexia, chills, vertigo, vomiting.  Additional information: Patient didn't receive other vaccine in four weeks. Started with fever and chills approximately 18 hours after the immunization. Early on morning of 09Nov2022 developed significant and debilitating vertigo with any type of position changes. Continued to fever for 48 hours despite Tylenol/Ibuprofen with a temperature around 101.1 F. Vertigo was significant enough to cause vomiting, limited ability to ambulate and also limited oral intake. Fever broke evening of 10Nov however Vertigo persisted requiring follow up with a medical provider and prescription medications. Facility type Vaccine: Doctor's office/urgent care. AE resulted in: Doctor or other healthcare professional office/clinic visit. Treatment drugs include Meclizine and Zofran. No Covid prior vaccination. No Covid tested post vaccination.